Position in GUTS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$98,871
-$376,058 QoQ
Shares Held
215,877
0.0% QoQ
Ownership
0.136%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026NORTHERN TRUST CORP holds $6,613,834,361 across 418 Biotechnology names. GUTS ranks #361 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,564,264 | $1,145,046,441 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
941,941 | $727,781,290 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
858,120 | $283,926,160 | |
| 4 | INSM |
INSMED Inc
|
1,294,000 | $211,594,876 | |
| 5 | RPRX |
Royalty Pharma plc
|
3,808,735 | $182,705,014 | |
| 6 | INCY |
Incyte Corp
|
1,849,726 | $174,096,208 | |
| 7 | MRNA |
Moderna, Inc.
|
2,952,041 | $149,963,680 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,403,642 | $104,234,453 |
All Filings in GUTS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $98,871 | 215,877 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $474,929 | 215,877 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $23,277 | 14,640 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $23,716 | 14,640 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $230,025 | 193,299 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $421,032 | 204,385 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $541,045 | 213,852 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $73,461 | 17,204 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $108,336 | 14,640 | Shares | Defined | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||